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Abstract
Beneficial effects of dietary phospholipids (PLs) have been mentioned since the early 1900’s in relation to different
illnesses and symptoms, e.g. coronary heart disease, inflammation or cancer. This article gives a summary of the
most common therapeutic uses of dietary PLs to provide an overview of their approved and proposed benefits;
and to identify further investigational needs.
From the majority of the studies it became evident that dietary PLs have a positive impact in several diseases,
apparently without severe side effects. Furthermore, they were shown to reduce side effects of some drugs. Both
effects can partially be explained by the fact that PL are highly effective in delivering their fatty acid (FA) residues
for incorporation into the membranes of cells involved in different diseases, e.g. immune or cancer cells. The
altered membrane composition is assumed to have effects on the activity of membrane proteins (e.g. receptors) by
affecting the microstructure of membranes and, therefore, the characteristics of the cellular membrane, e.g. of lipid
rafts, or by influencing the biosynthesis of FA derived lipid second messengers. However, since the FAs originally
bound to the applied PLs are increased in the cellular membrane after their consumption or supplementation, the
FA composition of the PL and thus the type of PL is crucial for its effect. Here, we have reviewed the effects of PL
from soy, egg yolk, milk and marine sources. Most studies have been performed in vitro or in animals and only
limited evidence is available for the benefit of PL supplementation in humans. More research is needed to
understand the impact of PL supplementation and confirm its health benefits.
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Introduction
Phospholipids (PLs) are amphiphilic lipids found in all
plant and animal cell membranes, arranged as lipid
bilayers (Figure 1). The PLs found in most cell mem-
branes are basically glycerophospholipids (GPLs), which
consist of fatty acids (FAs) esterified to a glycerol back-
bone, a phosphate group and a hydrophilic residue (e.g.
choline, resulting in phosphatidylcholine or lecithin).
The backbone of a PL can also be the long chain
amino-alcohol sphingosin instead of glycerol. These PL
are classified as sphingophospholipids, the most repre-
sentative being sphingomyelin, found in high quantities
in brain and neural tissue, consisting of sphingosin
esterified to one FA and phosphocholine.
Figure 1 shows a simplified illustration of a typical
eukaryotic cellular plasma membrane. Besides glycero-
phospholipids (GPLs) and sphingomyelin (SPM), biolo-
gical membranes are also made up of glycolipids and
cholesterol, as well as of integral and peripheral mem-
brane proteins. Most of the GPLs arrange themselves
forming a lipid bilayer, in which the polar (hydrophilic)
regions of the PL are directed towards the outer surface
of the membranes and the hydrophobic regions towards
the inner membrane compartment.
GPLs extracted from food products (e.g. soybeans, egg
yolk, milk, or marine organisms like fish, roe or krill)
are defined as “dietary GPLs”. They can be ingested
either with normal diet or as supplements. Naturally
occurring GPLs, either from plant or animal origin, pre-
dominantly contain an unsaturated FA in the sn-2 posi-
tion1, such as oleic, linoleic or linolenic acid, or the
proinflammatory arachidonic acid (usually from animal
origin) or the anti-inflammatory eicosapentaenoic acid
(usually from marine origin), while the sn-1 position
predominantly carries a saturated FA, such as stearic
acid or palmitic acid.
The mean dietary intake of GPLs is not exactly
known. In a normal diet, the daily intake of PC is
approximately 2-8 grams [1]. Foods with a high PC
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content are e.g. egg yolk, pig or chicken liver, soybeans
and beef.
In the intestine, GPLs are almost completely absorbed
(> 90%). In the lumen most of them are hydrolysed at
the sn-2 position by the pancreatic phospholipase A2
(pPLA2) and then taken up by the enterocytes as free
fatty acids (FFAs) and lysoPL. Both can be reesterified
to GPLs and enter the bloodstream incorporated in chy-
lomicrons and, in a small proportion, in very low den-
sity lipoproteins (VLDL). However, it has been assumed
that almost 20% of intestinal PLs are absorbed passively
and without hydrolysation [2], and preferentially incor-
porated directly into high density lipoproteins (HDL).
From HDL, GPLs can be transferred into the plasma
membranes of numerous cells (e.g. liver, muscle, kid-
neys, lung, tumor cells, etc.) as their corresponding lyso-
form after enzymatic activity of the lecithin-cholesterol-
acyl-tranferase (LCAT) [3]. This mechanism is complex
and has not yet been completely elucidated, but it has
been shown that dietary GPLs are able to deliver their
FAs for incorporation into cellular membranes, thus
altering the membrane composition of the cells [4].
Since GPLs are the main PL class found in cell mem-
branes, their FA composition has a major impact on
membrane characteristics, for example membrane fluid-
ity and therefore formation of lipid rafts. Lipid rafts are
dynamic membrane micro-domains with a high content
of cholesterol and PLs predominantly carrying saturated
FAs and have been involved in apoptosis and cellular
proliferation [5]. These micro-domains are in charge of
organising and regulating important cellular functions.
An important example is the lipid raft dependent tri-
merisation of Fas-receptor (CD95), pivotal for the induc-
tion of apoptosis after Fas-binding. Furthermore, PLs
play an important role in providing unsaturated FAs as
precursors for eicosanoid synthesis. The origins of the
FA, therefore their chain length and degree of satura-
tion, contribute to the biological properties of the
synthesized eicosanoids. Depending on which PL-bound
FAs are available in the cell membrane, different types
of eicosanoids are synthesized (e.g. the proinflammatory
PGE2 synthesized from arachidonic acid and the predo-
minantly anti-inflammatory PGE3 from eicosapentaenoic
acid) [6].
In summary, the oral application of dietary GPLs with
a specific FA composition has the potential to cause
defined alterations of the FA composition of membrane
PLs within a certain cell type. As a consequence, cellular
functions, including signaling and transport, as well as
the activity of membrane bound enzymes, could be
modulated by dietary PLs and hence contribute to the
health benefits described throughout this review article.
Different types of dietary GPLs vary in their FA-com-
position and headgroup, and therefore may have differ-
ent effects. Table 1 provides an overview of the regular
composition of dietary GPLs; and table 2 provides a
selection of PL products used as supplements in the
published papers included in this review.
The main characteristics of dietary GPL are:
◦ Soybean GPLs are mainly characterised by their high
content of unsaturated FAs, namely linoleic acid (n-6
FA) bound to different types of PLs. The relative
amounts of the PL classes PC, phosphatidylethanola-
mine (PE) and phosphatidylinositol (PI) are similar.
◦ Main PL class of egg yolk is PC. The FA distribution
represents mainly unsaturated FAs, in particular oleic acid.
◦ Milk GPLs are not only characterised by having PC
and PE as main PL classes, but also by containing high
quantities of SPM. Bound FAs are both saturated and
unsaturated.
◦ The main PL class of marine-derived GPLs is PC,
predominantly binding the unsaturated eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA); both are
n-3 FAs.
On the cellular level, the effects of membrane modifi-
cations caused by PLs are easy to detect by in vitro ana-
lysis. In contrast, membrane alterations are difficult to
determine in vivo and especially in humans. Until now,
the gastrointestinal metabolism of dietary GPLs as well
as the mechanism of their incorporation into cellular
membranes to achieve beneficial health effects has not
been thoroughly explored. One main and obvious diffi-
culty for these kinds of studies is that GPLs are nor-
mally found in almost all kinds of food products. The
different types of GPLs can not be separated within
each food product and at the same time other lipid
components like triglycerides (TGs) are also included.
This makes the determination of the metabolic pathway
of each GPL difficult to analyse and thus their health
effects can not be clearly defined.
Figure 1 Schematic illustration of the plasma membrane of an
eukaryotic cell.
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This review article summarises the published health
effects of dietary GPLs for different groups of illnesses.
Most of these nutritional studies have focussed only on
the health effects of GPLs, but, like mentioned before,
the underlying physiological mechanisms have not been
addressed. However, a few studies have shown that the
FA composition of cellular membranes can be influenced
by dietary GPLs. Around 100 articles dealing with the
effects of dietary PLs were reviewed, including human
clinical trials as well as in vitro and animal studies.
Phospholipids in inflammatory processes
Inflammation is a biological response to harmful stimuli,
such as pathogens or damaged cells, which is induced
and kept up by a biochemical cascade involving inflam-
matory mediators like cytokines, chemokines and eicosa-
noids. There is a growing scientific rationale for the use
of dietary PLs for the treatment of inflammatory dis-
eases to regulate the inflammatory reaction.
Hartmann et al. investigated the effect of PC (unknown
source) in chemically-induced arthritis (with carrageen)
in rats. They found a significantly reduced development
of arthritis after PC supplementation, most likely due to
an inhibition of the neutrophil leukocyte-mediated
inflammatory reaction [7]. Further, Eros et al. could show
that soybean PC (Lipoid S45, see table 2) alone can limit
the inflammatory process of joints in a chronic murine
model of rheumatoid arthritis (collagen-induced arthritis)
when fed during the onset of disease [8]. They found oral
pretreatment of mice with soy PC to effectively impair
leukocyte adhesion to the endothelial layer as well as to
decrease the expression of inducible Nitric Oxide
Synthase (iNOS) and thereby decrease the degree of
synovial angiogenesis. In another study they investigated
the same dietary supplementation of soybean PC (Lipoid
S45, see table 2) in mice after inducing pleurisy. Inflam-
matory reaction was characterised by pulmonary leuko-
cyte infiltration, mast cell degranulation and increased
iNOS, all parameters were suppressed by dietary soybean
PC [9]. Soybean PC was therefore shown to be effective
in reducing inflammatory reactions in arthritis and simi-
lar inflammatory processes in a murine model.
Table 1 Important dietary glycerophospholipids (GPLs): PL and FA composition
Soybean GPL
*
Egg yolk
GPL*
Milk GPL * Marine GPL *
PL’s+ PC 10-15% [111] 65-70% [111] 26% [110] 87.5%§
PE 9-12% [111] 9-13% [111] 30% [110] 5.8%§
PI 8-10% [111] – 9% [110] 2.2%§
PS 1-2% [111] – – –
SPM – 2-3% [111] 22% [110] 3.4%§
Unsaturated Fatty
acids
Total 75.5% [111] 54% [111] 28% [M.S. unpublished Data] 84.3%§
Oleic 10.7% [111] 32.3% [111] 20% [M.S. unpublished Data] 29.2%§
Linoleic 58% [111] 16.7% [111] 2.2% [M.S. unpublished Data] 2.5%§
Linolenic 6.8% [111] – 0.5% [M.S. unpublished Data] 2.7% [L.T. unpublished
Data]
Arachidonic – 5% [111] 0.1% [M.S. unpublished Data] 1.9% [L.T. unpublished
Data]
eicosapentaenoic – – – 18.8%§
docosahexaenoic – – – 22.8%§
other – – 5% [M.S. unpublished Data] –
Saturated
Fatty Acids
Total 22.4% [111] 46% [111] 68.7% [M.S. unpublished Data] 15.6%§
Palmitic 18.4% [111] 37% [111] 31.8% [M.S. unpublished Data] 14.1% [L.T. unpublished
Data]
Stearic 4% [111] 9% [111] 15% [M.S. unpublished Data] 2.9% [L.T. unpublished
Data]
other – – C4:0 to C14:0 24.1% [M.S. unpublished
Data]
–
* Mean values of different analytical data. The table contains the typical composition of the referred GPL, which may differ depending on its source and the
employed analytical method. Information was extracted from the mentioned literature or from the analytical data sheets of the manufacturers.
+ Phosphatidylserine (PS) is also an important GPL found mostly in meat. A good source is bovine brain. This compound is not mentioned here, since it is not
widely addressed in the present review.
§ Data from BioSea Management AS.
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Table 2 Selected examples of dietary glycerophospholipids (GPLs) used as supplements in the mentioned studies
Brand name/Product
name
Product information given by the producer/publication
Dietary GPLs from soybean
Essentiale® 80% PC, other ingredients: soybean oil, castor oil, ethanol, ethylvanillin, methoxyacetophenon, food colourings, gelatine,
tocopherol and water; as capsules. Nattermann & Cie. GmbH
Essentiale L® or Buer®
Lecithin
Soybean GPL (purity unknown), other ingredients: riboflavin, phosphate sodium, pyridoxine hydrochloride,
cyanocobalamin, sodium panthotenate and nicotinamide; as capsules.
Nicholas Piramal India Ltd. Or Nycomed Germany GmbH
Lipoid S45® 45-50% soybean PC, 10-18% PE, max. 4% LysoPC. Typical FA composition: 58-65% linoleic acid, 12-17% palmitic acid, 8-
12% oleic acid and other FAs; as powdered compound.
Lipoid GmbH
Lipostabil® 93% PC, other ingredients: ethanol, benzyl alcohol, deoxycholic acid, sodium hydroxide, sodium chloride, tocopherol and
water; as liquid formulation. Artegodan GmbH
PC-55 55% PC, 30% PE, 3% PI, other PLs and triglycerides; as powdered compound. TwinLab [77]
PhosChol 80% soybean lecithin (Phosal 75A), 18% TG, other ingredients: anethole, tocopherol and paraben. Fatty acid composition:
mainly linoleic acid; as liquid formulation.
Nutrasal LLC Co. [66]
Phospholipon®100 100% native soybean PC as a powdered compound.
Phospholipid GmbH
Phospholipon®90G 94-100% PC, LysoPC and tocopherol as powdered compound.
Phospholipid GmbH
Polyunsaturated PC PC with 40-52% linoleic acid (n-6); as powdered compound.
Rhone-Poulenc Rorer GmbH [104]
Polyunsaturated Lecithin 60% PC, 30% PE, 6% phosphatidic acid,
3% monophosphatidylinositol, 3% LysoPC, 80% unsaturated fatty acids, 20% other fatty acids; as powdered compound.
American Lecithin Co. [102]
Soy Lecithin 31.7% PC, 20.8% PE, 3% PS, 17.5% PI, 2% phosphatidic acid, other ingredients unknown; as powdered compound.
Herbarium, Brazil [99]
Soy Lecithin 40.4% PC, 35.1% PE, 24.5% PI. Fatty acid composition: 56.6% linoleate, 18.9% palmitate and other fatty acids; as powdered
compound. Central Soya, Fort Wayne IN [53]
Soybean PC 96.5% PC as powdered compound.
Tsujiseiyu Matsuzaka Co. [29]
Soybean PC capsules 64% soybean PC, 30% soybean oil, other PLs, ethanol and water. Fatty acid composition: 64% linoleic acid, 12% palmitic
acid, 12% oleic acid, 8% linolenic acid and 4% stearic acid; as liquid compound. Nutrition et Santé, Revel, France [54]
Sterpur P-30 30% PC, 21% PE and 8% PI, other ingredients unknown; as granulate. Stern-Lecithin & Soya GmbH [39,112]
Dietary GPLs from milk
Lacprodan® PL-20 27% PC, 22% PE, 8% PI, 27% SPM, 12% PS and other ingredients; as powdered compound.
Arla Foods Ingredients [57]
Sphingomyelin Extracted from bovine milk, unknown composition, as powdered compound. Avanti Polar Lipids, Inc. [34]
Dietary GPLs from marine origin
MPL (Neptune Krill oil,
NKO™)
40% PL, 15% EPA and 9% DHA bound to PLs and neutral lipids, other ingredients: unsaturated FAs, saturated FAs,
gelatine, glycerine, water; as liquid formulation packed in gelatine capsules. Jarrow Formulas Co.
MPL (Vitalipin®) 29% PC, 18% EPA and 26% DHA bound to PLs and neutral lipids, other ingredients: polyenes, monounsaturated FAs,
saturated FAs, other fats; as liquid formulation packed in gelatine capsules. Membramed health food GmbH
Squid meal PC PC contains 35.2% palmitic acid, 9.2% EPA, 43% DHA and 13% other FAs; as powdered compounds.
Nippon chemical Feed Co. Ltd. [30]
Dietary GPLs from animal origin
Bovine liver PI 100% PI as powdered compound. Avanti Polar Lipids, Inc. [61]
Brain cortex derived PS Unknown composition. Fidia Farmaceutical S.p.A. [89]
Pig brain GPLs PLs with aprox. 23% saturated fatty acids, 53% monounsaturated fatty acids and 24% n-6 fatty acids, as powdered
compound. Laboratoires Ponroy, France [71]
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Prostanoids play a central role in inflammatory pro-
cesses and pain. The isoenzymes cyclooxygenase (COX)-
1 and -2 are responsible for the oxygenation of two
essential FAs, dihomo-gamma-linolenic acid (DGLA, a
n-6 FA) and EPA (a n-3 FA), resulting in prostanoids of
the series-1 and series-3, which are less inflammatory
than those of series-2, which result from the oxygena-
tion of arachidonic acid (AA, a n-6 FA). Since DGLA
and EPA are competitive inhibitors of AA for enzymatic
COX conversion, they are responsible for reducing
inflammatory properties, by decreasing the enzymatic
conversion of prostanoids of the series-2. Dietary
sources of DGLA and EPA (e.g. borage or fish oil) could
therefore alleviate inflammatory reactions.
Marine phospholipids (MPL), carrying mainly n-3 FAs,
have been described to reduce inflammatory reactions
by the inhibition of prostaglandins of the series-2
(PGE2). Krill oil (see table 2), a PC rich marine product
extracted from an antarctic zooplankton crustacean was
investigated for its anti-inflammatory effects in patients
with cardiovascular and/or rheumatoid arthritis and ele-
vated C-reactive protein (CRP) levels in a randomised,
placebo-controlled, double-blind, manufacturer-spon-
sored study. Treatment with krill oil (dosage of 300 mg
daily) significantly reduced CRP levels and arthritic
symptoms such as pain, joint stiffness and functional
impairment [10].
Cachexia is a complex and impairing loss of body
weight observed in different diseases i.e. cancer, AIDS,
congestive heart failure, etc., which is caused largely by
a systemic inflammatory process. Cachexia worsens the
outcome of the primary disease and a successful therapy
is not yet available. Taylor et al. could confirm in a clin-
ical trial that oral supplementation of cachectic tumor
patients with 1.5 g/d MPL (Vitalipin®, see table 2) could
alleviate tumor-associated weight loss while noticeably
improving quality of life and physical activity [4]. These
clinical results might further be explained by the inhibi-
tory effects of PC on the pro-inflammatory TNFa-
induced NFB activation as shown in vitro by Treede et
al.. NFB causes activation of a number of pro-inflam-
matory genes as well as ATP-dependent ubiquitin pro-
teasome formation, which leads to proteolysis of muscle
cells, a pathway increased in cachectic wasting [11].
This means that the supplementation with MPLs during
diseases causing cachexia could be recommended as
supportive therapy to achieve stabilisation of the cachec-
tic syndrome and therefore improve therapeutic results.
Another interesting therapeutic use of PL from marine
sources is the application of Krill oil (see table 2) for the
effective treatment of premenstrual syndrome (PMS).
Since menstrual pain and cramps are supposed to be
caused by n-6 FA mediated inflammation, the supple-
mentation with n-3 FA could alleviate the mentioned
symptoms. During a double-blind randomised clinical
trial, krill oil was shown to be significantly more effec-
tive in reducing abdominal pain, swelling, breast tender-
ness and joint pain when compared to n-3 FAs from
fish oil [12]. Furthermore, Sampalis et al. found an
improvement in the emotional symptoms of PMS with
the supplementation of krill oil, since brain PLs, which
have a high content of DHA, are involved in brain func-
tion. Krill oil has the potential to modulate neurotrans-
mitters and thereby, to positively affect the emotional
and psychological symptoms in women with PMS. This
means that the n-3 FAs bound to PLs are much more
effective than FFAs in alleviating the mentioned symp-
toms, which could be explained by a much more effi-
cient transport mechanism.
Non steroidal anti-inflammatory drugs (NSAIDs) inhi-
bit the activity of the COX enzymes (COX-1 and -2),
reducing the production of prostaglandins responsible
for inducing pain symptoms and the related inflamma-
tory reactions. Since NSAIDs (e.g. aspirin and ibuprofen)
are not specific in inhibiting COX-2, the cyclooxygenase
isoenzyme which is expressed under pathological condi-
tions, they also affect the activity of the constitutively
expressed COX-1 isoenzyme. COX-1 is - among other
functions - in charge of regulating the production of
natural mucus in the stomach to protect it from the
secreted gastrointestinal (GI) acid and from pepsin
hydrolysis during digestion, by catalyzing the production
of PGE2 from AA, which reduces gastrointestinal acid
production. This is the reason for the well known GI
side effects of NSAIDs, since the GI protective effects of
the mucus production are impaired by the unwanted
inhibition of COX-1. However, a GI protective effect of
PLs was shown with soybean PC (Phospholipon®100,
see table 2), which reduced gastric mucosal lesions in
rats after the treatment with NSAIDs (aspirin, indo-
methacin, phenylbutazone, diclofenac, piroxicam and
sudoxicam). Co-administration of Phospholipon®100
with NSAID improved the drug tolerability and reduced
the typical GI side effects, likely due to an increased
production of cytoprotective mucosal PGE2 [13]. Since
soy PC does not contain AA, the necessary AA for the
production of PGE2 was probably formed by the con-
version of linoleic acid (n-6 FA) to AA by the enzymes
delta-6-desaturase, elongase and delta-5-desaturase.
These GI-cytoprotective effects of PLs were also seen in
patients presenting GI symptoms caused by a regular
use of NSAIDs [14]. All patients were supplemented
with Phospholipon®100 for 14 days resulting in ulcer
healing as well as diminished upper abdominal pain.
Another study by Dial et al. describes the beneficial
effects of PC pretreatment (Phospholipon®90G, see
table 2) in preventing LPS induced permeability changes
of the GI tract in rats. This study shows that PC has
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protective effect not only due to supporting the PGE2-
production [15].
Already in 1984 it has been found that (milk) PLs
have a protective effect against gastric acid. An investi-
gation in rats showed that treatment with milk reduced
the ulcerating effects of intraluminal application of HCl.
This effect was attributed to the concentration of di-pal-
mitoyl-PC (DPPC), which is one of the major compo-
nents of milk PLs [16]. During the following years the
same group of researchers could substantiate their origi-
nal findings with a large number of animal and human
studies [17-19].
Besides the mentioned anti-inflammatory effects of
GPLs in the GI tract, Stremmel et al. have found posi-
tive results of soybean PC (Sterpur P-30, see table 2)
with regard to ulcerative colitis. One component of the
colonic mucus is PC, arranged as lamellar layer and act-
ing as mucosal defense [20]. The authors found a 70%
decrease of mucosal PC in ulcerative colitis. In various
clinical trials the authors found positive effects of the
administration of delayed-release oral PC to patients
with ulcerative colitis. They discussed that a physico-
chemically increased hydrophobicity of the intestinal lin-
ing could be responsible for the protective effects on
preventing and healing inflammatory ulcerative colitis,
since a defective PC layer contributes to inflammation;
and second, PC has the ability to be integrated into the
plasma membrane of enterocytes, modulating their sig-
nal transduction [21]. This has been shown for example
in the study of Treede et al. where they found that PC
was able to change the association between proteins and
lipid microdomains, inhibiting thereby TNF-a-induced
inflammation in Caco-2 cells [22].
In addition, PLs have shown to improve the pharma-
cokinetics of some drugs including NSAIDs. Lichtenber-
ger et al. and Dial et al. have demonstrated soybean PC
(formulation of NSAIDs with Phospholipon®90G, see
table 2) to increase the anti-inflammatory and analgesic
activity of NSAIDs in acute and chronic models of
arthritis, by enhancing its transport and bioavailability
[13,23-25]. Therefore, the administration of NSAIDs
together with PLs could be an interesting attempt to not
only enhance their analgesic activity, but also in dimin-
ishing the known side effects and reducing the risks
caused by their regular use.
Phospholipids and cancer
Several studies have described beneficial effects of PLs
in tumor and metastasis inhibition. Some investiga-
tions have shown that cancer cell membranes acquire
particular properties, which vary from those found in
the differentiated progenitor cells. For example, the
membrane of neoplastic cells showing the ability to
metastasize have lost their adhesive characteristics as
found in normal cells [26]. This enables cancer cells
to dissociate from their surrounding (tumor) tissue
and to migrate to other tissues or organs, causing
tumor metastases. The membrane of breast and pros-
tate cancer cells was shown to have a higher concen-
tration of lipid rafts (areas with high cholesterol
content) than their normal counterpart cells, which
was associated with higher apoptotic sensitivity (regu-
lated by its cholesterol content). Consequently, the
regulation of the composition and density of lipid rafts
could potentially alter cancer cell viability and meta-
static behaviour [27].
A number of studies have investigated PLs for their
ability to inhibit cancer growth. An in vitro study with
hepatic cancer cell lines showed a dose dependent
growth restraint when the cancer cells were cultured in
the presence of soy and egg yolk PC (96.5% pure PC
from soybeans and 99% pure PC from egg yolk) and
menaquinone-4 (vitamin K2) [28]. Supplementation with
PC and menaquinone-4 was also tested in rats, showing
a clear suppression of nodule formation (precursors of
hepatic cancer) and preneoplastic liver lesions in supple-
mented rats, compared to the control group. Although
the effects were more significant when administering PC
together with menaquinone-4, which act synergistically,
PC alone also showed a statistically significant reduction
of cancer cells via death ligands (i.e. Fas or TNF-a),
thereby promoting apoptosis by the activation of cas-
pase-8 and -3, resulting in PAP (poly(A)-polymerase)
inhibition. Due to the interesting results, the authors are
planning to examine these effects in a clinical trial,
where a PC supplementation (900 mg/day of PC) will be
used with the aim to prevent hepatocarcinogenesis in
humans [28,29].
Beyond the above mentioned effects of administering
NSAIDs together with PLs, i.e. the reduction of GI side
effects and the improvement of analgesic activity,
NSAIDs have also been shown to reduce growth of can-
cer cell lines [24]. Cancer patients commonly use
NSAIDs for pain management on a regular basis, which
causes GI side effects in most cases. Therefore, formula-
tions of NSAIDs bound to PLs could effectively reduce
bleeding and ulceration during pain therapy, while their
additional effects in preventing cancer cell growth
would be another advantage of this co-administration.
To this regard, Dial et al. demonstrated that in colon
cancer cell lines (SW-480, without expression of COX-
2) the combination of soybean PC (Phospholipon®90G,
see table 2) with NSAIDs, especially Ibuprofen-PC, had
greater potency to inhibit cellular DNA synthesis than
NSAIDs alone. Since SW-480 cells do not express
COX-2, the result must be independent of the COX-2
inhibition and was shown to be related to an inhibition
of phosphoinositol specific phospholipase C (PLC) and a
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subsequent suppression of protein kinase C, resulting in
reduced cancer cell growth [24].
Moreover, the administration of marine PLs (PC
extracted from squid meal and from starfish, both con-
taining n-3 FAs) was shown to inhibit growth of chemi-
cally induced colon cancer in vitro. A significantly
increased apoptosis rate was found in rats being fed
with PC from squid (rich in DHA) and PC from starfish
(rich in EPA), which was explained by an increased lipid
peroxidation rate as a consequence of structural and
functional shifts in the cellular membrane [30]. This was
also observed after combining DHA or EPA (as free
fatty acids or bound to PLs) with sodium butyrate
(NaBt). In addition, they investigated the impact of
other MPLs (PC together with PS extracted from star-
fish) as chemotherapeutic agent on Caco-2 tumors in
vivo, showing a growth inhibition and an induction of
cell differentiation. This effect was again more pro-
nounced when adding NaBt to the PL due to an addi-
tional antiproliferative effect. The mechanism by which
the n-3-FAs exert their inhibitory effect on tumor
growth is still not completely understood. However, PLs
must play an important role since FAs bound to PLs
have a more pronounced effect when compared to the
respective FFAs [31]. The results suggested that marine
PC and PS carrying the n-3 FAs EPA and/or DHA can
be used as colon cancer chemotherapy agents alone or
in presence of NaBt [32].
Moreover, a mouse model was used to show that diet-
ary sphingomyelin (SPM, see table 2) had a drastic pre-
ventive effect on colon cancer formation [33,34]. A
possible mechanism of action of sphingolipids in sup-
pressing colon carcinogenesis is the action of sphingoli-
pid metabolites like sphingosine, sphingosine-phosphate
and ceramide to induce apoptosis in a human adenoma
cell line.
Recently, a strong antimetastatic effect of empty lipo-
somes consisting only of hydrogenated PC and choles-
terol was reported in two different orthotopic pancreatic
tumor models in mice (AsPC1, LNCaP) while the
growth of the primary tumors was not affected [35,36].
Investigating the underlying mode of action revealed
that the PC degradation product, namely hydrogenated
lysoPC, is most likely pivotal for the observed effect.
After liposome accumulation in tumor tissues, lysoPC
can be generated from PC by phospholipase A2 (PLA2)
which is known to be highly expressed by numerous
aggressive cancer cells, including pancreatic cancer cells
[37]. Hydrogenated lysoPC was found to be rapidly
taken up by the tumor cells in vitro, which leads to a
remarkable increase of hydrogenated FAs in the cellular
membranes and to a loss of their adhesion properties.
Thus, adhesion of the tumor cells to endothelial cells
and to platelets, both key factors in the process of
metastasis, is strongly reduced and might therefore
explain the antimetastatic effects of the PC containing
liposomes. In a metastasis model using B16.F10 mouse
melanoma cells, the pretreatment with hydrogenated
lysoPC resulted in at least 50% inhibition of metastatic
lesions in mice [38].
Phospholipids in the regulation of blood lipid profiles
and cardiovascular risks
The oral supplementation with dietary PLs has been
investigated extensively in relation to blood lipid profiles
and cardiovascular risks. Several authors reported a sig-
nificant total cholesterol lowering effect of soybean PLs
in patients with primary hyperlipidaemia [39-41]. This
was not observed in patients with normal lipid levels, due
to opposed HDL and LDL responses to supplementation.
After 30 days of treatment, total cholesterol, LDL choles-
terol as well as TGs were significantly decreased, while
HDL cholesterol was significantly increased [42]. These
effects were also described by Kirsten et al. in patients
with diabetes mellitus (which have commonly pathologi-
cal lipoprotein profiles) supplemented with polyenylpho-
sphatidylcholine (PPC) over a 2 month period [43].
Patients with coronary artery disease and hypercholes-
terolemia resistant to low lipid diet and treated with
Lovastatin® normally achieve a reduction in TG, total
cholesterol and LDL levels but simultaneously display
an increased platelet activity, which is an independent
risk factor for cardiovascular disease. Many studies
reporting treatment with Lipostabil® (soybean PLs, see
table 2) in patients with coronary heart disease have
suggested not only beneficial effects in reducing choles-
terol levels by up to 50%, but also in preventing platelet
aggregation [44-46]. For this reason, a combined therapy
composed of lipid lowering medication and PLs could
be a more helpful approach for the treatment of
hypercholesterolemia, at the same time controlling pla-
telet function [47]. Marine PLs (MPL) were also shown
to have remarkable lipid lowering effects. A placebo-
controlled, manufacturer-sponsored study with krill oil
came to favorable results regarding the effect on blood
lipid profiles in patients suffering from hyperlipidaemia
[48]. Krill oil supplementation led to a significant reduc-
tion of total cholesterol, LDL and TG levels, while HDL
increased significantly. Similar observations were made
by Taylor et al., where a significant HDL increase could
be seen in tumor patients after six weeks of MPL sup-
plementation (Vitalipin®, see table 2), while total and
LDL cholesterol decreased [4]. Since the supplementa-
tion with traditional fish oil (FAs bound to TG instead
of PL) lowers only blood TG levels [49], but has no
effect on LDL and HDL levels [50], PLs must be respon-
sible for the observed beneficial changes of blood lipid
profiles.
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Similar effects to those of MPL on plasma lipid pro-
files were found for soybean PC. In a study with patients
suffering from hypertension and obesity a dietary sup-
plementation with sunflower oil in combination with
soybean PC (unknown composition) was compared to
sunflower oil alone. The PL supplementation was shown
to reduce serum total cholesterol level, LDL, apo A1
(apolipoprotein A1), apoB and fibrinogen, consequently
leading to a positive clinical outcome regarding hyper-
tension [51,52]. Furthermore, animal studies performed
by Wilson et al. demonstrated that the cholesterol low-
ering effect of a lipid lowering diet could be enhanced
by the supplementation of soybean PC (Central Soya,
see table 2) because it does not reduce plasma HDL
levels, which are usually reduced during a lipid lowering
diet [53]. They compared a diet containing soybean PC
with a diet containing equivalent amounts of linoleate
and choline, to find that the PC diet resulted in stronger
hypocholesterolaemic effects. The analysed fatty streak
area was significantly smaller in animals fed with the
soybean PC supplementation, compared to those fed
with the linoleate and choline diet.
High apoA1 levels have also been described to be pro-
tective against arteriosclerotic disease. Polichetti et al.
investigated the effect of soybean PC supplementation
(SPC Nutrition et Santé capsules, see table 2) on the
apoA1 system in patients with type IIA hypercholestero-
lemia. They found that soybean PC increased signifi-
cantly the level of apoA1, decreasing simultaneously
apoA2 and apo E levels and stimulating therefore the
reverse cholesterol transport, which contributes to
reduced risk of arteriosclerosis [54].
Noh et al. have reported that sphingomyelin (SPM,
unknown composition), a sphingosine phospholipid and
major component of milk phospholipids as well as
hydrogenated egg PC, has a significant effect on blood
cholesterol levels [55,56]. The involved mechanism sug-
gested by the authors is a similar effect to that of phy-
tosterols, which may slow the rate of luminal lipolysis,
micellar solubilisation and transfer of micellar lipids into
the enterocytes. However, a clinical study investigating
the lipid lowering effect of a SPM enriched butter milk
formulation (Lacprodan® PL-20, see table 2) containing
2-3 times more SPM than the normal dietary intake, did
not show any significant decrease of either plasma lipids
or lipoprotein levels [57].
Different mechanisms have been proposed and experi-
mentally explored to explain the beneficial effects of
GPLs on blood lipid profiles. In that context, the enzy-
matic activity of the blood lipid metabolism after oral or
intravenous administration of PC has been investigated.
The results show that PC causes a beneficial shift in
blood lipid profiles, mostly reducing cholesterol levels,
by altering the activities of important enzymes in lipid
metabolism (see table 3: Enzymatic activity of the lipid
metabolism after administration of PLs (adapted from
Gundermann 1993 [58])).
Other explanations for the effects of PL on blood lipid
profiles are related more to the biophysical effects of PL,
influencing the intestinal absorption of cholesterol and
other lipids. In the intestine, PLs have emulsifier proper-
ties and the ability to form a fat-water emulsion with
cholesterol and other lipids, forming vesicles or micelles.
The cholesterol transport from the intestine into the
enterocytes depends on the emulsification of the dietary
fats with biliary secreted PC - or PC from the diet. In
the presence of bile salts, vesicles are converted into
micelles, which is ideal for lipid intestinal absorption
[1]. PLs play an important role during lipid intestinal
absorption by facilitating the formation of micelles (as
PC and later as lysoPC which is formed from PC by
pPLA2). Monomolecularly dissolved fat molecules,
which are easily released from those micelles, are subject
to uptake by enterocytes. It has been speculated that the
addition of excess PL to the intestine by PC supplemen-
tation may lead to the formation of oversized micelles,
preventing enzymes to reach micellar core content and
reducing lipid and cholesterol absorption [1,59]. More-
over, intestinal PLs are also able to interact with the cel-
lular membrane of enterocytes, reducing their
cholesterol absorptive capacity [1]. Some authors have
described that the degree of saturation and the length of
FAs bound to PLs also controls the quantity of choles-
terol absorbed in the intestine. The higher the degree of
saturation and the longer the chain length of the FA,
the less cholesterol is absorbed [55,56,60]. One possible
explanation for this finding is the fact that PL carrying
saturated FAs are poor substrates for pPLA2, therefore
hindering the enzyme from accessing the micellar lipids
(formed mainly of cholesterol, mono- and diglycerides,
and coated with saturated PL) and in consequence
impairing the cholesterol uptake [56].
The increase of HDL cholesterol in the blood after PL
supplementation could be attributed to the fact that PLs
can partially be absorbed intact by the intestine and are
incorporated preferentially into HDL [2]. Furthermore,
PLs are the substrate for the lecithin-cholesterol acyl-
transferase (LCAT), which catalyses the conversion of
HDL3 to HDL2, thereby collecting cholesterol from per-
ipheral tissues and increasing HDL levels [53].
Cholesterol lowering effects were also observed when
administering phosphatidylinositol (PI) extracted from
bovine liver (see table 2) to rabbits. The authors found
that PI is primarily incorporated into HDL lipoproteins,
which have direct contact to the cellular membranes of
peripheral tissue. Via this pathway, PI has the ability to
change membrane properties, influencing the intracellu-
lar signalling cascade and stimulating cholesterol efflux
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from peripheral cells due to an alteration of intracellular
calcium levels. The discharged cholesterol is transported
by HDL into the liver for biliary secretion (vascular cho-
lesterol homeostasis), causing a significant cholesterol
lowering effect [61]. Furthermore, it has been demon-
strated that the increase of intracellular calcium levels
promotes the catabolism of HMG-CoA reductase [62].
Due to the alteration of intracellular calcium levels by
PI, it could be assumed that PI also has the ability to
reduce cholesterol via this cellular homeostatic pathway
[61].
High homocysteine concentrations have been
described to be associated with a greater risk for devel-
oping cardiovascular disease. Homocysteine is a non-
protein amino acid synthesized from methionine.
Homocysteine can be recycled into methionine or con-
verted into cysteine with B-vitamins acting as co-factors.
Since betaine (synthesized from choline) has been
shown to diminish plasma homocysteine concentrations
[63-65], a choline supplementation could also contribute
to the same effect. In a double-blind, placebo-controlled
clinical trial Olthof et al. investigated the supplementa-
tion with soybean PC (PhosChol, see table 2) on homo-
cysteine plasma concentrations in men with mildly
elevated levels. They found that PC was able to reduce
homocysteine levels, thus being able to reduce the risk
of cardiovascular disease [66].
Independent of blood lipid profiles, PC has recently
been correlated to the risk of cardiovascular disease
through its metabolites [67]. The authors observed that
intestinal micro flora metabolised PC to trimethylamine
N-oxide (TMAO), which was considered to promote
cardiovascular disease together with two other PC meta-
bolites, betaine and choline. They found an up-regula-
tion of macrophage foam cell formation, which
promotes atherosclerosis, when TMAO, betaine and
choline levels were increased in blood [67]. But, the
conclusion that intake or supplementation of PC directly
affects the risk for developing cardiovascular disease can
not be drawn from this study. The correlation was
observed with TMAO or choline alone, but no experi-
ment correlated cardiovascular disease with supplemen-
tation of PC itself. Furthermore, each intestinal segment
has different composition of the micro flora. The article
does not describe in detail in which part of the intestine
the feeding tube was placed.
The results reviewed here clearly show that PLs do
affect blood lipid profiles in a beneficial way, and the
clearest evidence was shown for marine PL containing
predominantly EPA and DHA as well as for soybean
PC. However, the mode of action has been not investi-
gated thoroughly and more research is needed to clarify
the mechanisms behind these positive effects.
Phospholipids and neurological development/
neurological disorders
Age related memory impairment represents a gradual,
but physiologically normal deterioration of memory
function, which affects virtually every human being. It is
known that during aging the lipid composition of brain
cells changes. The amount of polyunsaturated n-3 FAs
(3-PUFA) in the brain tends to decrease with age, con-
sequently membrane fluidity is decreased and choliner-
gic activities via retarded Na+- and Ca+-channels in the
membranes are reduced, since they require PC and
PUFAs for their excitability and neurotransmitter release
[68]. One can assume that memory decline and the
diminished learning abilities found in the elderly are
consequences of a decreased quantity of PC and/or
PUFAs in the brain tissue. PLs have been demonstrated
to be important and effective carriers of essential
PUFAs, e.g. docosahexaenoic acid (DHA) to the brain.
Some authors have proven the preferential incorporation
of DHA bound to lysoPC over free or TG bound DHA
into the young rat brain [69,70]. For this reason, oral
supplementation of PL carrying n-3 PUFAs (which is a
special characteristic of PLs from marine origin) may
play an important role, not only in the elderly, but also
during pregnancy and infancy, where DHA provision
into the brain is essential for neurological development.
Table 3 Enzymatic activity of the lipid metabolism after administration of PLs (adapted from Gundermann 1993 [58])
Enzyme Activity after PL
administration
Consequence
Lipoprotein lipase (LPL) ⇑ Acceleration of the breakdown of lipoproteins rich in TG, which results in a reduction of LDL
and VLDL
Hepatic triglyceride lipase
(HTGL)
⇑
Acyl-cholesterol
acyltransferase (ACAT)
⇓ Reduction of cholesterol ester deposition in cells
Cholesterol esterase ⇑ Hydrolysis of cholesterol esters in the cells. Free cholesterol can be transferred to the blood
and incorporated into HDL by LCAT, which results in higher HDL-level
Lecithin cholesterol acyl
transferase (LCAT)
⇑
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However, studies have shown that a supplementation
with PL purified from pig brains, from egg yolk and
from soybeans, which are rich in DHA, may improve
learning abilities and visual function in age related
impairment and during an n-3 PUFA deficiency. Supple-
mentation could restore the ideal composition of PUFAs
in the brain cell membrane, in which PLs have the
potential of facilitating their transport [68,71,72]. Also,
supplementation with dilinoeyl-PC (DLPC) in rats has
shown to facilitate hippocampal synaptic transmission in
the brain, improving thereby their spatial learning and
memory abilities [73]. A further study investigated the
effects of DLPC and palmitoyl-oleoyl-PC (POPC) in rats
and in patients with cognitive disorders. Oral co-intake
of DLPC and POPC resulted in better learning and
memory abilities, and improvement of cognitive disor-
ders [74].
Moreover, chronic alcohol consumption depletes PL
in brain cell membranes, especially PC. It is discussed
that alcohol supports the depletion of enzymatic and
non enzymatic antioxidant systems (e.g. glutathione)
from the cell membranes, which in turn leads to
increased levels of lipid peroxidation (especially PUFA)
in the brain, but also in other cells such as erythrocytes.
Since the brain has a high PUFA content and few anti-
oxidative systems compared to other tissues, it is extre-
mely susceptible to lipid peroxidation, which is the
initial step for the removal of a PL from the cell mem-
brane. Thus, the cholesterol/PL ratio increases in cell
membranes, leading to higher membrane rigidity and
decreases cell deformability. On the other hand, acetal-
dehyde as product of the ethanol metabolism is able to
bind to proteins forming acetaldehyde-adducts, which
inhibit or damage enzymes and deplete the antioxidant
status, augmenting the above mentioned effects, which
could lead to serious degenerative modifications in the
brain, resulting in neurological disorders. Jayaraman et
al. have described the role of PC (Essentiale L, see table
2) as antioxidative agent in the treatment of alcohol
induced brain changes. They could show that after etha-
nol application, PC administration prevented oxidative
stress on erythrocytes (including the RBC membranes)
and various brain regions in rats by restoring antioxida-
tive mechanisms. Thus, the authors suggested PC as a
useful antioxidant after alcohol ingestion [75].
Furthermore, PC might be a useful choline donator
for the treatment of neurological diseases. During fetus
development, choline is important for the brain tissue,
since it serves on one hand as component of the cellular
membrane and on the other hand as acetylcholine (Ach)
precursor. It was demonstrated that rat pups showed
better memory results when mothers were supplemen-
ted with choline during pregnancy. Choline had an
influence on cellular proliferation, apoptosis and on
epigenetic DNA properties, affecting brain development
and thereby lifelong memory characteristics [76]. In a
placebo controlled clinical trial, Ladd et al. found that
the supplementation of PC (TwinLabs PC-55II, see table
2) in normal college students lead to an improvement in
explicit memory due to increased choline supply and to
improved cholinergic function [77].
Contrary to cognitive impairment, which could be a
physiological normal deterioration, Alzheimer’s disease
is of different nature, generally irreversible and has a
pathological background. An example regarding Alzhei-
mer’s disease shows that the membranes of affected
brain cells have lower concentration of GPLs, i.e. etha-
nolamine plasmalogensIII. The proposed mechanism
behind the PL decrease is a higher activity of the plas-
malogene-selective phospholipase A2 (PLA2), causing an
increased release of free FAs and eicosanoids, which are
coupled to lipid peroxidation and, most importantly,
changing the membrane composition (membrane integ-
rity, permeability and the structure of lipid microdo-
mains) [78]. Since Alzheimer’s disease are also linked to
inflammatory processes, anti-inflammatory drugs might
have the potential to slow its progression [79]. In this
regards, Pandey et al. investigated the effects of (DLPC)
on neuronal cells, finding reduced neuronal inflamma-
tory activities through the inhibition of NFB and
MAPK [80]. All of these factors contribute to neurode-
generation in Alzheimer’s disease, so that a supplemen-
tation with dietary GPLs could be effective in altering
the cellular composition of brain cells and contributing
to better therapeutic results. Other clinical studies have
not found beneficial effects of PLs (especially PC) in
Alzheimer’s disease and since it is a complex pathology,
more research is needed to clarify the inconsistent
results.
Besides the mentioned effects of PC in improving
memory and cognition, the highly specialised GPL,
phosphatidylserine (PS), has an outstanding importance
in the function of brain and neural cells. PS is able to
revitalise memory, learning, concentration and even
vocabulary skills - all those functions which have been
found to be decreased with age. PS was originally
extracted from bovine cortex, now it is also made from
soya PC by enzymatic head group exchange.
In the last 25 years PS has been subject of a large
number of randomised, double blind, placebo-controlled
clinical trials. Together with more than 2.800 scientific
papers about brain and neurological function, it is by far
the best studied GPL for brain performance [81,82].
With aging, the sharpness of memory and cognition
functions decreases, condition called Age Related Cogni-
tive Decline (ARCD). These functions may lead to
severe neurological disorders, not only in sick subjects,
but also in clinically healthy individuals, which have
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difficulty in accepting the effects of cognition impair-
ment [83]. A study of Crook et al. investigated short
term memory function (primary parameter was the
name/face acquisition and remembering the phone
numbers) with the supplementation of PS (unknown
composition). After just 3 weeks of PS supplementation
they observed a statistically significant improvement of
the physiological loss of cognition. In comparison to the
control group, patients with PS supplementation had
“rolled back the clock” of their cognitive age for 12
years in average [84]. Furthermore, a review paper
described 9 double blind, placebo- controlled clinical
trials investigating the outcome of PS treatment of a
total of 1.224 patients affected by ARCD and/or early
Alzheimer’s Disease. It was shown that PS supplementa-
tion provided a strongly significant improvement in cog-
nition and memory functions compared to the placebo
group [85].
PS has further benefits regarding other brain activities
like coping with stress and fighting depression. In young
and healthy male patients the supplementation of PS
showed to lower the production of stress hormones
linked to strenuous exercise and eased stress-related
mood symptoms [86]. Recent studies with soya PS sup-
plementation showed stress lowering effects and
improvements on concentration parameters in young
and healthy subjects. Interestingly, the effects were more
pronounced in patients with introverted personal beha-
viour [87].
Furthermore, supplementation with PS has been
described to improve cognitive, neuropsychological and
daily life performance through raising glucose levels in
the brain. In patients with probable Alzheimer’s disease,
the brain metabolism was analysed with Positron Emis-
sion Tomography (PET) showing a threefold increase of
glucose levels [88].
Another effect of PS is the stimulation of acetylcholine
synthesis, which triggers the release of neurotransmitters
from the vesicles to the synaptic gap. This effect may
explain the reason of significant improvements of the
physical performance in cycling tests after intravenous
administration of brain cortex-derived PS (see table 2)
[89].
The fact that the different FA composition of bovine
derived PS or soya derived PS does not have any clinical
relevance led to the hypothesis that naturally occurring
PS found in milk GPLs could also have similar effects.
Two clinical studies investigating the daily intake of a
milk PL concentrate rich in PS on working memory,
allostastic loadIV and acute stress response showed posi-
tive results. Compared to placebo-exposed individuals,
there was a tendency to shorter reaction times in the
working memory task, suggesting better performance in
milk PL treated subjects. The two treatment groups did
not significantly differ regarding their endocrine stress
response. However, subjects in the PL-arm showed a
blunted psychological stress response with a higher
stress load. The results show beneficial effects on cogni-
tive performance with the supplementation of milk PL,
which is most probably attributed to its PS content.
However, the benefits of milk PS may only be visible in
chronically stressed subjects [90,91].
Improvements of memory, cognition and motility were
also shown in patients with Parkinson’s disease after
supplementation with soybean PLs (formulation contain-
ing 25% PC), although no beneficial effects were
observed regarding Parkinson’s disease itself [92]. Stu-
dies with PC were also performed in other neurological
diseases e.g. in patients with Friedreich’s ataxia and
patients with Gilles la Tourette’s syndrome, but no rele-
vant clinical results were observed [93-95].
During cerebral infarction the brain content of PLs
may also decrease and contribute to the related compli-
cations. To this regard Shi et al. showed that supple-
mentation with lecithin (unknown composition) after
the onset of cerebral infarction showed effective results
by preventing the decrease of brain PLs [96].
Phospholipids and immunological function
The cholesterol/PL ratio (C/PL) in the cell membrane
increases with age. These changes in the composition of
cell membranes have consequences for their properties
and functions. For example in lymphocytes an increase
of the C/PL-ratio reduces their immunological function.
Meczek et al. showed that the membrane viscosity of
lymphocytes can be modulated by recovering the opti-
mal C/PL-ratio. Therefore, it is expected that an
increase of the PL content in lymphocyte cell mem-
branes could restore the immunological function in the
elderly [97]. An in vitro study by Rivnay et al. investi-
gated the C/PL-ratio in lymphocytes after exposure to
PC (Lecithin liposomes, unknown source). Lymphocytes
of old mice had an increased C/PL-ratio in their mem-
branes. Supplying the mice with the mentioned PC
enhanced the proliferative response of lymphocytes.
This effect was not significant in lymphocytes of young
mice, supporting the theory that external PC (e.g. diet-
ary PC) restores the optimal C/PL ratio in the affected
lymphocyte membrane and probably in all other cells,
too, maintaining their normal cellular functions [98].
The effect of dietary soy PC (Herbarium, see table 2)
on the macrophage phagocytic capacity and on lympho-
cyte number in response to concanavalin A (ConA)V sti-
mulation was examined in vivo in rats. Lymphocyte
number and macrophage phagocytic capacity were sig-
nificantly improved with soy PC supplementation, indi-
cating a modulatory positive effect of PC on the
immune function [99].
Küllenberg et al. Lipids in Health and Disease 2012, 11:3
http://www.lipidworld.com/content/11/1/3
Page 11 of 16
In a further study, Jannace et al. investigated the
effects of soy PC (unknown product) on phagocytosis,
arachidonic acid (AA) concentrations and on neutrophil
killing in healthy individuals. They found a significant
improvement of polymorphonuclear leukocyte (PMNL)
phagocytic and killing activity, and a significant increase
in AA release in individuals fed with soybean PC, com-
pared to individuals receiving placebo. The AA release
indicated the ability of soy PC to change the membrane
composition of PMNL, resulting in an improvement of
its immunological functions. The effects must be attrib-
uted to PLs, since individuals fed with safflower or soy-
bean oil (TG instead of PLs) did not show the same
immunological benefits [100].
Phospholipids and liver diseases
GPLs have been widely prescribed for the treatment of
hepatic disorders including viral hepatitis and alcohol
induced liver damage. A recent review by Gundermann
et al. shows that essential PLs (purified extract of PPC
derived from soybean) are indeed beneficial in the men-
tioned hepatic disorders. Although the use of essential
PLs was characterized to be evidence-based medicine,
more controlled clinical trials are required to determine
its benefits [101]. The next paragraphs include some
examples of the use of GPLs to treat liver disease.
During alcohol consumption the liver cells display
reduced membrane PL levels. Many studies have shown
that after supplementation with polyenylphosphatidyl-
choline (PPC, especially DLPC), the provided PL may be
directly incorporated into the membrane of liver cells;
normalising, among others, the activity of membrane-
bound enzymes (i.e. phosphatidylethanolamine methyl-
transferase, PEMTVI) and reducing alcohol induced liver
injury. For example, the study of Lieber et al. investi-
gated the effect of soybean PPC supplementation (see
table 2) during a 10 year period of chronic alcohol con-
sumption in primates. In contrast to animals treated
only with ethanol, animals treated with ethanol and soy-
bean PPC showed reduced fibrinogenic liver damage
and consequently had less cirrhosis development [102].
The mechanisms discussed could be attributed to the
PPCs ability to prevent acetaldehyde-mediated collagen
accumulation, thus preventing liver fibrosis [103]. This
effect was also investigated in humans during a rando-
mised placebo-controlled clinical trial continuing for
almost 20 years, showing that PPC ameliorated liver dis-
ease in drinkers. Other positive properties of DLCP
regarding alcohol induced liver damage are its ability to
reduce hepatocyte apoptosis, as well as generation of
TNF-a by Kupffer cells and lipid peroxidation [59]. The
PC supplementation was shown to prevent not only the
development of alcohol induced cirrhosis, but already
the early liver changes induced by alcohol consumption
(e.g. fatty liver and hyperlipidemia). Usually, alcohol
intake induces an increase in plasma lipids, which are
later transported to and accumulated in the liver (mainly
TG and cholesterol ester) causing the alcohol induced
hepatic damage [104]. Soybean DLPC supplementation
(see table 2) was shown to prevent lipid accumulation in
the liver, by reactivating the ethanol induced inhibition
of mitochondrial FA oxidation, thereby reducing liver
damage [104]. All the above mentioned effects were
attributed to the whole PL, since the effects were not
observed when supplementing FFA or the head group
alone. Also, an animal study in rats demonstrated that
PLs provided much better results in reducing liver TG
levels when compared to a TG supplementation with
almost the same FA composition as the PL supplemen-
tation [105].
In a clinical trial including patients with chronic alco-
hol consumption and alcohol induced liver damage,
treatment with soybean PC (Lipostabil®, see table 2) was
shown to be effective in improving liver related symp-
toms (e.g. cholestasis and icterus) while the hepatic anti-
oxidant status was also restored [106].
Furthermore, PL supplementation was shown to be
effective not only in improving alcohol related liver dis-
ease, but also after hepatic damage caused by toxins and
virus infections. Some studies showed an amelioration
of hepatic symptoms and an enhancement of liver func-
tions with soybean PC supplementation in patients pre-
senting non alcoholic liver damage [102,107]. Moreover,
soybean PC (Essentiale®, see table 2) was given to
patients presenting dramatic circulatory problems and
simultaneous hepatic disorders, resulting in enhance-
ment of hemodynamics, intrahepatic cholestasis, liver
function and in the general lipid metabolism [108].
With regard to viral liver infections (hepatitis), a rando-
mised clinical study was carried out in patients with
hepatitis B or C. They received a combined therapy
composed of the standard therapy interferon alpha
(IFN) and either PPC or placebo. The results showed
positive effects in patients suffering from hepatitis C,
but not in patients presenting hepatitis B. The combined
therapy of PPC and IFN improved the response rate of
the standard therapy (IFN only) and the curative effect
lasted longer compared to patients treated with IFN and
placebo [109]. The fact that the observed effects were
not seen in patients with hepatitis B could be attributed
to the different pathophysiological cell damage of the
two viral diseases.
Not only plant derived PLs, but also the supplementa-
tion with PL-rich dairy milk extract has shown to pro-
tect from liver damage by reducing total liver lipid, liver
TG and total cholesterol. This was analysed by Wat et
al. in mice fed with a high fat diet and PL-rich dairy
milk extract (15% PE, 15% PC, 12% SPM, 8% PS, 4% PI
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and other ingredients). They could show that the
expression of enzymes in charge of the hepatic FA
synthesis was significantly decreased and that the bile
acid production was also reduced, which might be due
to a lower intestinal absorption of cholesterol. This
study suggests that PLs from milk and dairy products
have the potential to protect not only against cardiovas-
cular events by reducing hyperlipidemia, but also to
reduce hepatomegaly and hepatic steatosis [110].
Conclusions and Discussion
This review provides an overview of the potential uses
of GPLs as active ingredients for the treatment of differ-
ent diseases. Many investigations revealed impressive
health benefits of GPL supplementation without notice-
able side effects.
It is impressive how GPLs, even though being “only” a
food-component, are able to interact with the cellular
membranes, changing their compositions (and probably
their lipid microstructure and the lipid rafts) and
thereby influencing a vast quantity of signalling pro-
cesses and enzymatic activities. Since there have been
many studies with remarkable effects performed during
the past two decades, one could assume that GPLs are a
“miracle drug”. One explanation for the mentioned out-
standing effects might be that our eating behaviour has
changed during the last 1-2 centuries towards a subopti-
mal GPL-uptake, namely not enough GPLs and/or GPLs
carrying the “wrong” FAs ("proinflammatory” n-6 FAs
from i.e. meat and egg). The optimal n-3 to n-6 FAs
ingestion is about 1:5. With the typical western diet the
actual ratio is estimated to be 1:20, which is far below
the recommendations. It has been shown that the sup-
plementation with GPLs rich in n-3 FAs have the ability
to compensate the “n-3 FA deficiency” in a more effi-
cient way than other n-3 FA supplements (e.g. as TG or
as free FAs) [100]. One could speculate that uptake of
n-3 FA as GPLs are more efficiently incorporated into
cellular membranes of different organs, thus affecting
positively the membrane microstructure and its func-
tion. Thus, the benefits of GPLs reported in almost all
studies could represent only the reestablishment of the
normal GPL- and n-3 FAs requirements, so that GPLs
as supplements could be very helpful in improving a
great variety of health conditions. Since there are no
side effects reported so far, GPLs have the potential to
be consumed in a broader spectrum, that is, for many
disorders at a time (as a regulatory mechanism by balan-
cing the mentioned diet impairments regarding GPLs).
Furthermore, a higher uptake of the right type of GPLs
might also be recommended for healthy people as a pre-
vention strategy to improve public health. This can be
achieved by a regular uptake of GPLs as supplements
and/or by preferential intake of food with sufficient and
the “right” content of GPLs. Once more, it has become
clear, that a balanced and healthy diet has positive
effects in preventing and/or in stabilising/improving dis-
eases, now increasing awareness about the potential
importance of GPLs.
In contrast to the sometimes impressive effects of
GPLs, the scientific explanation behind these effects is
far from sufficient. The entire metabolism of GPLs has
not yet been completely investigated and many ques-
tions remain to be answered. More research is needed
to understand the role of GPLs after their ingestion and
how they interact with the various processes of our
complex metabolism. There are still many effects which
remain to be discovered and results from larger clinical
trials are eagerly awaited.
Endnotes
I The sn nomenclature is based on the stereospecific
numbering of the carbon atoms of a glycerol molecule.
It is used when a molecule has a chiral center (a carbon
atom which has no symmetry), in this case, the glycerol
backbone of a PL.
II 1 g of TwinLab PC-55 supplies 0,15 g of choline.
III Plasmalogens are ether lipids composed of glycerol,
a vinyl residue, a FA and a PL.
IV Allostatic load is a hightened neural response as a
consequence to repeated stress.
V ConA was used for activating lymphocytes
VI The PEMT enzyme is in charge of regenerating
hepatic PC, which is normally decreased during alco-
holic liver damage
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